Press Releases

InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

March 25, 2019
--Co-inventor of original CTLA4-antibody and immuno-oncology innovator to expand the Company's clinical development expertise--
Read more

Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial

March 21, 2019
Drug Name : docetaxel + ritonavir
Read more

ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

March 19, 2019
- Recognition for outstanding and innovative cancer research
Read more

Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers

February 20, 2019
Sapreme Technologies has been awarded a 6.8 M€ grant by the European Union.
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers

Modra Pharmaceuticals Expands Management Team and Provides Corporate Update

December 19, 2018
-- Colin Freund has joined as CEO -- Dr. Edwin De Wit appointed Head of Oncology Development -- Dr. Alan Barge appointed Chai...
Read more
Modra Pharmaceuticals Expands Management Team and Provides Corporate Update

ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018

November 13, 2018
Leiden, The Netherlands, November 13, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announce...
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018

Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline

November 02, 2018
Maastricht, The Netherlands, 2nd November 2018 - Cristal Therapeutics, a clinical stage pharmaceutical company developing targ...
Read more
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline

Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer

October 24, 2018
Maastricht, The Netherlands, 25th October 2018 - Cristal Therapeutics, a clinical stage pharmaceutical company developing uniqu...
Read more
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer

InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

October 01, 2018
--Two poster presentations highlight INT-1B3's immune-system activation and CD8+ T cell-driven anti-tumor response in addition...
Read more
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board

September 10, 2018
10th September 2018, Windsor, UK: Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next...
Read more
Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board

Home > Press Releases

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds